Plaintiffs bringing US antitrust claims against Boehringer aim to amend complaint
( September 22, 2026, 15:27 GMT | Official Statement) -- MLex Summary: Plaintiffs bringing US antitrust claims against Boehringer Ingelheim Pharmaceuticals for allegedly manipulating the US Food and Drug Administration’s patent listing process to unlawfully thwart generic competition in multiple markets asked a federal judge to grant them leave to amend their complaint after the previous complaint was dismissed. “The proposed amendment does not plead a new scheme or any new claims; it merely fleshes out the anticompetitive scheme already alleged in the operative complaint, with facts unearthed in discovery,” they said. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.